FrancophonIA/ELRC3.0 huggingface dataset:
English: In the event of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever), treatment must be stopped and re-introduction of STAYVEER is not to be considered.
Estonian: oksendamine, palavik, kõhuvalu, kollatõbi, ebatavaline letargia või väsimus, gripile sarnanev sündroom
English: After oral administration, the systemic exposure is proportional to dose up to 500 mg. At higher oral doses, Cmax and AUC increase less than proportionally to the dose.
Estonian: Suuremate suukaudsete annuste puhul tõusevad Cmax- ja AUC-tasemed aga proportsionaalsest vähem.
English: Cartons contain 56 or 112 film coated tablets (STAYVEER 125 mg film-coated tablets).
Estonian: Pappkarp sisaldab 56 või 112 õhukese polümeerikattega tabletti (STAYVEER 125 mg õhukese polümeerikattega tabletid).
English: STAYVEER 62.5 mg film-coated tablets Orange-white, round, biconvex, film-coated tablets, embossed with “62,5” on one side.
Estonian: STAYVEER, 62,5 mg õhukese polümeerikattega tabletid Oranžikasvalged ümmargused kaksikkumerad kaetud tabletid, mille ühele küljele on reljeefselt kirjutatud tekst “62,5”.
English: FUTURE 3/Extension, elevations in liver aminotransferases ≥ 3 × ULN were observed in 2% of patients.
Estonian: Laste kontrollrühmata uuringutes FUTURE 1/2 ja FUTURE 3/jätku-uuring täheldati 100 pulmonaalse arteriaalse hüpertensiooniga lapse andmete koondanalüüsis 2% patsientidest maksa aminotransferaaside taseme tõusu ≥ 3 × ULN.
English: Common (may affect up to one in 10 people):
Estonian: Sage (võivad esineda kuni 1 inimesel 10st):
English: > 5 and ≤ 8 × ULN The result should be confirmed by a second liver test; if confirmed, treatment should be stopped and aminotransferase levels monitored at least every 2 weeks.
Estonian: > 5 ja ≤ 8 × ULN Tulemust tuleb kinnitada teise maksatestiga.
English: STAYVEER 125 mg film-coated tablets Each film-coated tablet contains 125 mg bosentan (as monohydrate).
Estonian: STAYVEER, 125 mg õhukese polümeerikattega tabletid Iga õhukese polümeerikattega tablett sisaldab 125 mg bosentaani (monohüdraadina).
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON WITH 56 AND 112 TABLETS
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED 56 JA 112 TABLETTI SISALDAV KARP
English: At steady state, bosentan plasma concentrations were 3- to 4-fold higher than with bosentan alone.
Estonian: Bosentaani tasakaalukontsentratsioonid koosmanustamisel olid 3 kuni 4 korda kõrgemad kui bosentaani eraldi manustamisel.
English: Development of testicular tubular atrophy and impaired fertility has been linked with chronic administration of endothelin receptor antagonists in rodents.
Estonian: Endoteliini retseptori antagonistide korduvat manustamist närilistele on seostatud munandijuhade atroofia tekkimise ja fertiilsuse halvenemisega.
English: • caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing abnormal flow of blood through the heart and lungs.
Estonian: põhjustades ebatavalist vere voolu läbi südame ja kopsude.
English: Cartons contain 56 film-coated tablets (STAYVEER 125 mg film-coated tablets).
Estonian: Karbid, mis sisaldavad 56 õhukese polümeerikattega tabletti (STAYVEER 125 mg õhukese polümeerikattega tabletid).
English: Each tablet contains 62.5 mg of bosentan (as monohydrate).
Estonian: Iga tablett sisaldab 62,5 mg bosentaani (bosentaanmonohüdraadina).
English: Oct _____
Estonian: Veebr ______ Juuni ______ Okt _____
English: Cartons contain 56 or 112 film coated tablets (STAYVEER 62.5 mg film-coated tablets).
Estonian: Pappkarp sisaldab 56 või 112 õhukese polümeerikattega tabletti (STAYVEER 62,5 mg õhukese polümeerikattega tabletid).
English: Rare (may affect up to one in 1000 people):
Estonian: Harv (võivad esineda kuni 1 inimesel 1000st):
English: If any of these apply to you, tell your doctor.
Estonian: Mis tahes nimetatud tingimuste esinemise korral võtke ühendust oma arstiga.
English: As a result, a significantly reduced effect of bosentan is expected when it is co-administered with rifampicin.
Estonian: Seetõttu tuleb arvestada, et manustades koos rifampitsiiniga väheneb oluliselt bosentaani efektiivsus.
English: STAYVEER 62.5 mg film-coated tablets are orange-white, round film-coated tablets with “62,5” on one side.
Estonian: STAYVEER 62,5 mg õhukese polümeerikattega tabletid on oranžikasvalged ümarad õhukese polümeerikattega tabletid, mille ühel küljel on „62,5”.
English: - STAYVEER 62.5 mg film-coated tablets: The active substance is bosentan as monohydrate.
Estonian: Mida STAYVEER sisaldab - STAYVEER 62,5 mg õhukese polümeerikattega tabletid: toimeaine on bosentaan monohüdraadina.
English: • Baseline values of liver aminotransferases, i.e., aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT), greater than 3 × the upper limit of normal (ULN; see section 4.4)
Estonian: (ALAT)) väärtused üle 3 korra kõrgemad normi ülemisest piirist (ULN; vt lõik 4.4)
English: Cartons contain 56 film-coated tablets (STAYVEER 62.5 mg film-coated tablets).
Estonian: Karbid, mis sisaldavad 56 õhukese polümeerikattega tabletti (STAYVEER 62,5 mg õhukese polümeerikattega tabletid).
English: 9 patients were newly initiated on PAH-specific medication during the study.
Estonian: 9 patsiendil alustati alles uuringus pulmonaalse arteriaalse hüpertensiooni spetsiifilist ravi.
English: No specific study has been performed in patients with pulmonary hypertension and concomitant left ventricular dysfunction.
Estonian: Pulmonaalse hüpertensiooni ja sellega kaasuva vasaku vatsakese puudulikkusega patsientidega pole eraldi uuringuid läbi viidud.
English: There was evidence of a mild thyroid hormonal imbalance induced by bosentan in rats.
Estonian: Rottidel täheldati bosentaani toimel kerget kilpnäärmehormooni taseme kõikumist.
English: The PAH for which STAYVEER is indicated can be:
Estonian: Pulmonaalne arteriaalne hüpertensioon, mille puhul STAYVEER on näidustatud, võib olla:
English: Pulmonary arterial hypertension patients with concomitant left ventricular failure
Estonian: Pulmonaalse arteriaalse hüpertensiooniga kaasuva vasaku vatsakese puudulikkusega patsiendid
English: Some patients taking STAYVEER were found to have abnormal liver function tests.
Estonian: Osal STAYVEER-ravi saavatest patsientidest on ilmnenud kõrvalekaldeid maksatalitluse analüüside tulemustes.
English: Each tablet contains 125 mg of bosentan (as monohydrate).
Estonian: Iga tablett sisaldab 125 mg bosentaani (bosentaanmonohüdraadina).
English: The accumulation of bosentan in hepatocytes leading to cytolysis with potentially severe damage of the liver, or an immunological mechanism, are not excluded.
Estonian: Ei välistata võimalust, et põhjus peitub bosentaani ladestumises maksarakkudesse, mis viib maksa võimalikku rasket kahjustumist põhjustava tsütolüüsini.
English: A 2-year carcinogenicity study in mice showed an increased combined incidence of hepatocellular adenomas and carcinomas in males, but not in females, at plasma concentrations about 2 to 4 times the plasma concentrations achieved at the therapeutic dose in humans.
Estonian: Kaks aastat väldanud kartsinogeensuse uuring hiirtel näitas inimeste terapeutilise annusega saavutatud plasmakontsentratsioonist 2...4 korda kõrgema plasmakontsentratsiooni korral hepatoomide ja kartsinoomide koosesinemise sagenemist isastel, kuid mitte emastel hiirtel.
English: Eisenmenger's physiology
Estonian: I LISA RAVIMI OMADUSTE KOKKUVÕTE
English: There are no studies to demonstrate beneficial effects of STAYVEER treatment on survival.
Estonian: STAYVEER-ravi elulemust parandavaid toimeid tõestavaid uuringuid ei ole läbi viidud.
English: In vitro, bosentan inhibits the bile salt export pump in hepatocyte cultures.
Estonian: Maksarakkude in vitro uuringud on näidanud bosentaani inhibeerivat mõju sapisoolade ekspordipumba tööle.
English: Breast-feeding is not recommended during treatment with STAYVEER.
Estonian: Imetamine STAYVEER-ravi ajal ei ole soovitatav.
English: STAYVEER is not recommended in paediatric patients with systemic sclerosis and ongoing digital ulcer disease.
Estonian: STAYVEERi ei soovitata kasutada süsteemse skleroosi ja sõrme- ja varbahaavanditega lastel.
English: No effect of bosentan on time to healing of digital ulcers was observed in either study.
Estonian: Kummaski uuringus ei täheldatud bosentaani mõju sõrmehaavandite paranemisajale.
English: Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH.
Estonian: Ravi peab määrama ja jälgima ainult pulmonaalse arteriaalse hüpertensiooni ravi kogemusi omav arst.
English: Uncommon (may affect up to one in 100 people):
Estonian: Aeg-ajalt (võivad esineda kuni 1 inimesel 100st):
English: Monthly pregnancy tests are recommended while you are taking STAYVEER and are of childbearing age.
Estonian: STAYVEER-ravi ajal on soovitatav teha igakuiseid rasedusteste, kui olete rasestumiseas.
English: Management in the event of clinical deterioration of PAH
Estonian: Ravi pulmonaalse arteriaalse hüpertensiooni kliinilise halvenemise korral
English: Bosentan is eliminated by biliary excretion following metabolism in the liver by the cytochrome P450 isoenzymes, CYP2C9 and CYP3A4.
Estonian: Bosentaani metabolism toimub maksas tsütokroomi P450 isoensüümide CYP2C9 ja CYP3A4 vahendusel ning metaboliidid eritatakse organismist sapiga.
English: In adult patients, STAYVEER treatment should be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily.
Estonian: Täiskasvanud patsientidel peaks STAYVEERi algannuseks olema 62,5 mg kaks korda ööpäevas nelja nädala jooksul.
English: Each film-coated tablet contains 125 mg bosentan (as monohydrate)
Estonian: Iga õhukese polümeerikattega tablett sisaldab 125 mg bosentaani (monohüdraadina)
English: STAYVEER 125 mg film-coated tablets Orange-white, oval, biconvex, film-coated tablets, embossed with “125” on one side.
Estonian: STAYVEER, 125 mg õhukese polümeerikattega tabletid Oranžikasvalged ovaalsed kaksikkumerad kaetud tabletid, mille ühele küljele on reljeefselt kirjutatud tekst
English: If it is possible that you could become pregnant, use a reliable form of birth control (contraception) while you are taking STAYVEER.
Estonian: Kui olete rasestumisvõimeline naine, kasutage STAYVEER-ravi ajal efektiivseid rasestumisvastaseid vahendeid.
English: Contents of the pack and other information What STAYVEER contains
Estonian: Kuidas STAYVEERi säilitada Pakendi sisu ja muu teave
English: • jaundice (yellowing of your skin or the whites of your eyes)
Estonian: • kollatõbi (naha ja silmavalgete kollaseks muutumine)
English: 164 ng·h/mL, n = 11).
Estonian: AUC 8,57 [1,28…57,2] ng·h/ml).
English: Each film-coated tablet contains 62.5 mg bosentan (as monohydrate)
Estonian: Iga õhukese polümeerikattega tablett sisaldab 62,5 mg bosentaani (monohüdraadina)
English: Intensified monitoring is recommended during the discontinuation period.
Estonian: Siiski soovitatakse annuseid vähendada järk-järgult
English: Tell your doctor immediately if you are breast-feeding.
Estonian: Imetamine Kui toidate oma last rinnaga, teatage sellest kohe oma arstile.
English: STAYVEER 125 mg film-coated tablets bosentan
Estonian: STAYVEER 125 mg õhukese polümeerikattega tabletid bosentaan
English: Glibenclamide: Co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of glibenclamide (a CYP3A4 substrate) by 40%, with potential significant decrease of the hypoglycaemic effect.
Estonian: Kui koos glibenklamiidiga (CYP3A4 substraat) manustati viie päeva jooksul kaks korda ööpäevas 125 mg bosentaani, vähenes glibenklamiidi plasmakontsentratsioon 40% võrra.
English: Renal impairment
Estonian: • naha sügelus
English: Control was placebo plus current therapy.
Estonian: Kontrollgrupile manustati platseebot ja eelnevalt kasutatud ravimeid.
English: STAYVEER 62.5 mg film-coated tablets bosentan
Estonian: STAYVEER 62,5 mg õhukese polümeerikattega tabletid bosentaan
English: Patients could receive additional PAH treatment as required in the open-label extension.
Estonian: Avatud jätkufaasis võisid patsiendid saada vajaduse korral täiendavat pulmonaalse arteriaalse hüpertensiooni ravi.
English: No dose adjustment is required in patients with renal impairment.
Estonian: Neerukahjustuse korral ei ole annuste kohandamine vajalik.
English: Tablet core:
Estonian: Infolehe sisukord
English: Erythema
Estonian: Õhetus
English: However, to avoid the possible occurrence of harmful clinical deterioration due to potential rebound effect, gradual dose reduction (halving the dose for 3 to 7 days) should be considered.
Estonian: (alandades annust kolmeks kuni seitsmeks päevaks poole annuseni), et vältida tagasilöögi efektina tekkida võivat ohtlikku kliinilist halvenemist.
English: Please see also section 3.
Estonian: Vt ka lõik 3 „Kuidas STAYVEERi kasutada”.
English: Maize starch
Estonian: Tadalafiil.
English: It is given once every three weeks as an infusion lasting 10 minutes.
Estonian: Ravimit manustatakse iga kolme nädala järel 10minutilise infusioonina.
English: The recommended dose is calculated using the patient's height and weight.
Estonian: Soovitatav annus arvutatakse patsiendi pikkuse ja kehamassi järgi.
English: The full EPAR for Pemetrexed Fresenius Kabi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pemetrexed Fresenius Kabi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It can also be used as a maintenance treatment in patients who have received a platinum-based chemotherapy.
Estonian: Ravimit tohib kasutada ka säilitusraviks patsientidel, kes on saanud plaatinapõhist keemiaravi.
English: What measures are being taken to ensure the safe and effective use of Pemetrexed Fresenius Kabi?
Estonian: Mis meetmed võetakse, et tagada Pemetrexed Fresenius Kabi ohutu ja efektiivne kasutamine?
English: • malignant pleural mesothelioma (a cancer of the lining of the lungs that is usually caused by exposure to asbestos), where it is used together with cisplatin in patients who have not received chemotherapy before and whose cancer cannot be removed by surgery;
Estonian: • pleura maliigne mesotelioom (teatud kopsukelmevähk, mida tavaliselt põhjustab kokkupuude asbestiga), kusjuures ravimit kasutatakse koos tsisplatiiniga patsientidel, kes ei ole varem keemiaravi saanud ja kelle vähkkasvajat ei saa kirurgiliselt eemaldada;
English: The Committee recommended that Pemetrexed Fresenius Kabi be approved for use in the EU.
Estonian: Komitee soovitas Pemetrexed Fresenius Kabi kasutamise Euroopa Liidus heaks kiita.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Fresenius Kabi.
Estonian: Kõrvalnähtude vähendamiseks tuleb patsiendil võtta kortikosteroide (põletikuvastased ravimid) ja foolhapet (teatud vitamiin) ning talle tuleb Pemetrexed Fresenius Kabiga toimuva ravi ajal süstida vitamiini B12.
English: No additional studies were needed as Pemetrexed Fresenius Kabi is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Estonian: Lisauuringuid ei olnud vaja, sest Pemetrexed Fresenius Kabi on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
English: • advanced non-small-cell lung cancer of the kind known as ‘non-squamous', where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
Estonian: • kaugelearenenud mitteväikerakk-kopsuvähi muu kui lamerakuline vorm, kusjuures ravimit kasutatakse koos tsisplatiiniga varem ravimata patsientidel või ainsa ravimina patsientidel, kes on varem saanud vähiravi.
English: Because Pemetrexed Fresenius Kabi is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pemetrexed Fresenius Kabi on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides' (the building blocks of DNA and RNA, the genetic material of cells).
Estonian: Pemetrekseed muundub organismis aine aktiivseks vormiks, mis blokeerib nukleotiidide (rakkude geenimaterjali DNA ja RNA komponendid) tekkes osalevate ensüümide toime.
English: This is a summary of the European public assessment report (EPAR) for Pemetrexed Fresenius Kabi.
Estonian: See on ravimi Pemetrexed Fresenius Kabi Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that Pemetrexed Fresenius Kabi is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Estonian: See tähendab, et Pemetrexed Fresenius Kabi on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Fresenius Kabi has been shown to be comparable to Alimta.
Estonian: Inimravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Pemetrexed Fresenius Kabi sarnane toime ravimiga Alimta.
English: Pemetrexed Fresenius Kabi is a cancer medicine used to treat two types of lung cancer:
Estonian: Pemetrexed Fresenius Kabi on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks:
English: For more information about treatment with Pemetrexed Fresenius Kabi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pemetrexed Fresenius Kabiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Pemetrexed Fresenius Kabi, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pemetrexed Fresenius Kabi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: When Pemetrexed Fresenius Kabi is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Estonian: Kui Pemetrexed Fresenius Kabit kasutatakse koos tsisplatiiniga, tuleb enne või pärast tsisplatiini annuse manustamist anda patsiendile antiemeetikumi (oksendamise ennetamiseks) ja vedelikke (dehüdratsiooni ennetamiseks).
English: Other information about Pemetrexed Fresenius Kabi
Estonian: Muu teave Pemetrexed Fresenius Kabi kohta
English: What is Pemetrexed Fresenius Kabi and what is it used for?
Estonian: Mis on Pemetrexed Fresenius Kabi ja milleks seda kasutatakse?
English: It is not intended to provide practical advice on how to use Pemetrexed Fresenius Kabi.
Estonian: Hindamisaruandes ei anta Pemetrexed Fresenius Kabi kasutamise praktilisi nõuandeid.
English: The active substance in Pemetrexed Fresenius Kabi, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Estonian: Pemetrexed Fresenius Kabi toimeaine pemetrekseed on antimetaboliitide rühma kuuluv tsütotoksiline ravim (ravim, mis hävitab poolduvaid rakke, näiteks vähirakke).
English: Why is Pemetrexed Fresenius Kabi approved?
Estonian: Miks Pemetrexed Fresenius Kabi heaks kiideti?
English: Pemetrexed Fresenius Kabi contains the active substance pemetrexed.
Estonian: Pemetrexed Fresenius Kabi sisaldab toimeainena pemetrekseedi.
English: Pemetrexed Fresenius Kabi pemetrexed
Estonian: Pemetrexed Fresenius Kabi pemetrekseed
English: The medicine can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of chemotherapy.
Estonian: Pemetrexed Fresenius Kabi on retseptiravim ja seda tohib manustada üksnes keemiaravi kasutamises kogenud arsti järelevalve all.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pemetrexed Fresenius Kabi have been included in the summary of product characteristics and the package leaflet.
Estonian: Pemetrexed Fresenius Kabi omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Therefore, the CHMP's view was that, as for Alimta, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu Alimta korral, ületab ka ravimi Pemetrexed Fresenius Kabi kasulikkus sellega kaasnevad riskid.
English: Pemetrexed Fresenius Kabi is a ‘generic medicine'.
Estonian: Pemetrexed Fresenius Kabi on geneeriline ravim.
English: How has Pemetrexed Fresenius Kabi been studied?
Estonian: Kuidas Pemetrexed Fresenius Kabit uuriti?
English: Pemetrexed Fresenius Kabi is available as a powder that is made up into a solution for infusion (drip) into a vein.
Estonian: Ravimit Pemetrexed Fresenius Kabi turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: How is Pemetrexed Fresenius Kabi used?
Estonian: Kuidas Pemetrexed Fresenius Kabit kasutatakse?
English: How does Pemetrexed Fresenius Kabi work?
Estonian: Kuidas Pemetrexed Fresenius Kabi toimib?
English: What are the benefits and risks of Pemetrexed Fresenius Kabi?
Estonian: Milles seisneb Pemetexed Fresenius Kabi kasulikkus ja mis riskid ravimiga kaasnevad?
English: Ebilfumin received a marketing authorisation valid throughout the EU on 22 May 2014.
Estonian: Ebilfumin on saanud müügiloa, mis kehtib kogu ELis, 22. mail 2014.
English: Further information on Ebilfumin can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/ebilfumin.
Estonian: Lisateave Ebilfumini kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/ebilfumin.
English: Ebilfumin is available as capsules (30 mg, 45 mg, and 75 mg).
Estonian: Ebilfumini turustatakse kapslitena (30 mg, 45 mg ja 75 mg).
English: What measures are being taken to ensure the safe and effective use of Ebilfumin?
Estonian: Mis meetmed võetakse, et tagada Ebilfumini ohutu ja efektiivne kasutamine?
English: Ebilfumin does not replace flu vaccination, and its use should be based on official recommendations.
Estonian: Ebilfumin ei asenda gripivastast vaktsineerimist ja selle kasutamisel tuleb lähtuda ametlikest soovitustest.
English: Ebilfumin (oseltamivir) EMA/205963/2019
Estonian: Ebilfumin (oseltamiviir) EMA/205963/2019
English: For adults with a weakened immune system (the body's natural defences), it is given for 10 days.
Estonian: Nõrgenenud immuunsüsteemiga (organismi looduslikud kaitsemehhanismid) täiskasvanutele antakse ravimit 10 päeva.
English: Ebilfumin (oseltamivir)
Estonian: Ebilfumin (oseltamiviir)
English: When Ebilfumin is used during a flu epidemic, it is given for up to 6 weeks.
Estonian: Kui Ebilfumini kasutatakse gripiepideemia ajal, tohib seda kasutada kuni 6 nädalat.
English: Side effects reported with Ebilfumin are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ebilfumini kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Ebilfumin can also be used as preventative treatment in exceptional cases, for instance when the seasonal flu vaccine may not provide sufficient protection and when there is a pandemic (a global epidemic of flu).
Estonian: Ebilfumini tohib kasutada erandkorras ka ennetusraviks, näiteks kui gripivaktsiin ei anna piisavat kaitset ja esineb pandeemia (ülemaailmne gripiepideemia).
English: For more information about using Ebilfumin, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Ebilfumini kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.